A systems biomedicine approach for chronotherapeutics optimization: Focus on the anticancer drug irinotecan

SEMA SIMAI Springer Series

Volumn , Issue 9788847025707, 2012, Pages 301-327

  Ballesta, Annabelle ^a   Clairambault, Jean ^a   Dulong, Sandrine ^b,c   Levi, Francis ^b,c  

^a INRIA ROCQUENCOURT   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85016443784     PISSN: 21993041     EISSN: 2199305X     Source Type: Book Series    
DOI: 10.1007/978-88-470-2571-4_16     Document Type: Chapter

References (44)

1. Ahowesso, C.: Approche expérimentale de la personnalisation de la chronothérapeutique par irinotecan. Thèse Université Paris–Sud 11 (2011)
2. Ahowesso, C., Piccolo, E., Li, X.M., Dulong, S., Hossard, V., La Sorda, R., Filipski, E., Tinari, N., Delaunay, F., Iacobelli, S., Levi, F.: Relations between strain and gender dependencies of irinotecan toxicity and UGT1A1, CES2 and TOP1 expressions in mice. Toxicol. Lett. 192, 395–401 (2010)
3. Ando, H., Yanagihara, H., Sugimoto, K., Hayashi, Y., Tsuruoka, S., Takamura, T., Kaneko, S., Fujimura. A.: Daily rhythms of P-glycoprotein expression in mice. Chronobiol. Int. 22, 655–665 (2005)
4. Ballesta, A., Dulong, S., Abbara, C., Cohen, B., Okyar, A., Clairambault, J., Levi, F.: A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery. PLoS Comput. Biol. 7, e1002143 (2011)
5. Balsalobre, A., Damiola, F., Schibler, U.: A serum shock induces circadian gene expression in mammalian tissue culture cells. Cell 93, 929–937 (1998)
6. Bernard, S., Cajavec-Bernard, B., Levi, F., Herzel, H.: Tumour growth rate determines the timing of optimal chronomodulated treatment schedules. PLoS Comput. Biol. 3, e1000712 (2010)
7. Brand, W., Schutte, M.E., Williamson, G., van Zanden, J.J., Cnubben, N.H., Groten, J.P., van Bladeren, P.J., Rietjens, I.M.: Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients. Biomed. Pharmacother. 60, 508–519 (2006)
8. Brown, S.A., Zumbrunn, G., Fleury-Olela, F., Preitner, N., Schibler, U.: Rhythms of mammalian body temperature can sustain peripheral circadian clocks. Curr. Biol. 12, 1574–1583 (2002)
9. Carr, A.J., Whitmore, D.: Imaging of single light-responsive clock cells reveals fluctuating free-running periods. Nat. Cell. Biol. 7, 319–321 (2005)
10. Chabot, G.G., Robert, J., Lokiec, F., Canal, P.: Irinotecan pharmacokinetics. Bull. Cancer. Spec No:11–20 (1998)
11. Combes, O., Barré, J., Duché, J.C., Vernillet, L., Archimbaud, Y., Marietta, M.P., Tillement, J.P., Urien, S.: In vitro binding and partitioning of irinotecan (cpt-11) and its metabolite, sn-38, in human blood. Invest. New Drugs. 18, 1–5 (2000)
12. Davies, B., Morris, T.: Physiological parameters in laboratory animals and humans. Pharm. Res. 10, 1093–1095 (1993)
13. De Buck, S.S., Mackie, C.E.: Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation. Expert Opin. Drug. Metab. Toxicol. 3, 865–878 (2007)
14. Falcone, A., Ricci, S., Brunetti, I., Pfanner, E., Allegrini, G., et al.: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotécan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotécan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 1;25, 1670–1676 (2007)
15. Filipski, E., Lemaigre, G., Liu, X.H., Mery-Mignard, D., Mahjoubi, M., Levi, F.: Circadian rhythm of irinotecan tolerability in mice. Chronobiol. Int. 21, 613–630 (2004)
16. Garufi, C., Vanni, B., Aschelter, A.M., Zappala, A.R., Bria, E., Nisticó, C., Sperduti, I., Cognetti, F., Terzoli, E.: Randomised phase II study of standard versus chronomodulated CPT11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients. Eur. J. Cancer. 42, 608–616 (2006)
17. Gholam, D., Giacchetti, S., Brezault-Bonnet, C., Bouchahda, M., Hauteville, D., Adam, R., Ducot, B., Ghémard, O., Kustlinger, F., Jasmin, C., Lévi, F.: Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer. Oncologist. 11, 1072–1080 (2006)
18. Giacchetti, S., Itzhaki, M., Gruia, G., Adam, R., Zidani, R., Kunstlinger, F., Brienza, S., Alafaci, E., Bertheault-Cvitkovic, F., Jasmin, C., Reynes, M., Bismuth, H., Misset, J.L., Levi, F.: Longterm survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann. Oncol. 6, 663–669 (1999)
19. Granda, T.G., D’Attino, R.M., Filipski, E., Vrignaud, P., Garufi, C., Terzoli, E., Bissery, M.C., Levi, F.: Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Br. J. Cancer 86, 999–1005 (2002)
20. Guo, Y., Lu, P., Farrell, E., Zhang, X., Weller, P.: In silico and in vitro pharmacogenetic analysis in mice. Proc. Natl. Acad. Sci. USA 104, 17735–17740 (2007)
21. Hansen, N.: The CMA evolution strategy: a comparing review. In: Towards a new evolutionary computation. Advances on estimation of distribution algorithms, pp. 75–102. Springer, Heidelberg (2006)
22. Izumo, M., Sato, T.R., Straume, M., Johnson, C.H.: Quantitative analyses of circadian gene expression in mammalian cell cultures. PLoS Comput. Biol. 2, e136 (2006)
23. Kanno, Y., Otsuka, S., Hiromasa, T., Nakahama, T., Inouye, Y.: Diurnal difference in CAR mRNA expression. Nucl. Recept. 2, 6 (2004)
24. Kornmann, B., Preitner, N., Rifat, D., Fleury-Olela, F., Schibler, U.: Analysis of circadian liver gene expression by ADDER, a highly sensitive method for the display of differentially expressed mRNAs. Nucleic Acids Res. 29, E51–1 (2001)
25. Kuramoto, Y., Hata, K., Koyanagi, S., Ohdo, S., Shimeno, H., Soeda, S.: Circadian regulation of mouse topoisomerase I gene expression by glucocorticoid hormones. Biochem. Pharmacol. 71, 1155–1161 (2006)
26. Lavery, D.J., Lopez-Molina, L., Margueron, R., Fleury-Olela, F., Conquet, F.: Circadian expression of the steroid 15 alpha-hydroxylase (Cyp2a4) and coumarin 7-hydroxylase (Cyp2a5) genes in mouse liver is regulated by the PAR leucine zipper transcription factor DBP. Mol. Cell. Biol. 19, 6488–6499 (1999)
27. Levi, F., Giacchetti, S., Zidani, R., Brezault-Bonnet, C., Tigaud, J., Goldwasser, F., Misset, J.L.: Chronotherapy of colorectal cancer metastases. Hepatogastroenterology. 38, 320–322 (2001)
28. Levi, F., Okyar, A., Dulong, S., Innominato, P.F., Clairambault, J.: Circadian timing in cancer treatments. Annu. Rev. Pharmacol. Toxicol. 50, 377–421 (2010)
29. Levi, F., Schibler, U.: Circadian rhythms: mechanism and therapeutics implications. Annu. Rev. Pharmacol. Toxicol. 47, 593–628 (2007)
30. Morgan, D.: The Cell Cycle, Principles of Control. In: Primers in Biology. New Science Press Ltd and Oxford University Press, Oxford (2007)
31. Ohdo, S., Makinosumi, T., Ishizaki, T., Yukawa, E., Higuchi, S., Nakano, S., Ogawa, N.: Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice. J. Pharmacol. Exp. Ther. 283, 1383–1388 (1997)
32. Okyar, A., Piccolo, E., Ahowesso, C., Filipski, E., Hossard, V., Guettier, C., La Sorda, R., Tinari, N., Iacobelli, S., Levi, F. : Strain- and sex-dependent circadian changes in abcc2 transporter expression: implications for irinotecan chronotolerance in mouse ileum. PLoS One 6, e20393 (2011)
33. Ortiz-Tudela, E., Mteyrek, A., Ballesta, A., Innominato, P.F., Levi, F.: Cancer chronotherapeutics. Experimental, theoretical and clinical aspects. In: Kramer, A., Merrow, M. (eds) Circadian clocks: overview and basic principles, Springer, Heidelberg, in press
34. Panda, S., Antoch, M., Miller, B., Su, A., Schook, A.: Coordinated transcription of key pathways in the mouse by the circadian clock. Cell 109, 307–320 (2002)
35. Pommier, Y.: Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 6, 789–802 (2006)
36. Preitner, N., Damiola, F., Luis Lopez, M., Zakany, J., Duboule, D., Albrecht, U., Schibler, U.: The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell 110, 251–260 (2002)
37. Slatter, J.G., Schaaf, L.J., Sams, J.P., Feenstra, K.L., Johnson, M.G., Bombardt, P.A.: Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug. Metab. Dispos. 28, 423–433 (2000)
38. Smith, M.R., Burgess, H.J., Fogg, L.F., Eastman, C.I.: Racial differences in the human endogenous circadian period. PLoS One 4, e6014 (2009)
39. Sothern, R., Halberg, F., Hrushesky, W.: Circadian stage not time of day characterizes dox-orubicin susceptibility rhythm of mice in continuous light. Annu. Rev. Chronopharmacol. 5, 385–388 (1988)
40. Stanton, B.A.: Summary of the speaker presentations: ABC transporters in liver, kidney, and intestine. Kidney International, 62, 1520–1521 (2002)
41. Storch, K.F., Lipan, O., Leykin, I., Viswanathan, N., Davis, F.C.: Extensive and divergent circadian gene expression in liver and heart. Nature 417, 78–83 (2002)
42. Tsukamoto, Y., Kato, Y., Ura, M., Horii, I., Ishitsuka, H., Kusuhara, H., Sugiyama, Y.: A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm. Res. 18, 1190– 1202 (2001)
43. Welsh, D.K., Yoo, S.H., Liu, A.C., Takahashi, J.S., Kay, S.A.: Bioluminescence imaging of individual fibroblasts reveals persistent, independently phased circadian rhythms of clock gene expression. Curr. Biol. 14, 2289–2295 (2004)
44. Zhang, Y., Yeager, R., Klaassen, C.: Circadian expression profiles of drug processing genes and transcription factors in mouse liver. Drug Metab. Dispos. 37, 106–115 (2009)